[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 100, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 481205, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 53, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1111627, "exercisedValue": 0, "unexercisedValue": 901500}, {"maxAge": 1, "name": "Mr. Bo  Kruse", "age": 51, "title": "Executive VP, Secretary, Treasurer & CFO", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 762332, "exercisedValue": 0, "unexercisedValue": 1770520}, {"maxAge": 1, "name": "Ms. Susan  Smith", "age": 52, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 574704, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 49, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 72, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Dugan", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 58, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 406275, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.61, "open": 13.58, "dayLow": 12.75, "dayHigh": 14.4407, "regularMarketPreviousClose": 13.61, "regularMarketOpen": 13.58, "regularMarketDayLow": 12.75, "regularMarketDayHigh": 14.4407, "beta": 0.774, "forwardPE": -35.75, "volume": 631769, "regularMarketVolume": 631769, "averageVolume": 390137, "averageVolume10days": 436770, "averageDailyVolume10Day": 436770, "bid": 12.76, "ask": 12.9, "bidSize": 100, "askSize": 300, "marketCap": 564640384, "fiftyTwoWeekLow": 4.6, "fiftyTwoWeekHigh": 20.9, "priceToSalesTrailing12Months": 6.682214, "fiftyDayAverage": 15.6214, "twoHundredDayAverage": 9.4206, "currency": "USD", "enterpriseValue": 490201536, "profitMargins": -0.25641, "floatShares": 25483087, "sharesOutstanding": 43872600, "sharesShort": 2328235, "sharesShortPriorMonth": 2100314, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.053200003, "heldPercentInsiders": 0.14513, "heldPercentInstitutions": 0.65973, "shortRatio": 6.85, "shortPercentOfFloat": 0.0638, "bookValue": 2.262, "priceToBook": 5.689655, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -21666000, "trailingEps": -0.49, "forwardEps": -0.36, "pegRatio": 0.31, "enterpriseToRevenue": 5.801, "enterpriseToEbitda": -20.117, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "YMAB", "underlyingSymbol": "YMAB", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "firstTradeDateEpochUtc": 1537536600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef4c7aed-ff51-3117-8a16-0b2c87e3c948", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.87, "targetHighPrice": 26.0, "targetLowPrice": 12.0, "targetMeanPrice": 21.43, "targetMedianPrice": 22.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 75749000, "totalCashPerShare": 1.726, "ebitda": -24367000, "totalDebt": 1181000, "quickRatio": 5.472, "currentRatio": 6.15, "totalRevenue": 84499000, "debtToEquity": 1.191, "revenuePerShare": 1.935, "returnOnAssets": -0.120220006, "returnOnEquity": -0.20932, "freeCashflow": -11456375, "operatingCashflow": -17585000, "revenueGrowth": -0.016, "grossMargins": 0.86414003, "ebitdaMargins": -0.28837, "operatingMargins": -0.3466, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-10"}]